The detectability of psilocybin, the psychoactive compound in hallucinogenic mushrooms, in standard drug screenings is generally low. Most common drug tests, such as urine drug screens used by employers, are designed to detect substances like opiates, amphetamines, cocaine, and marijuana metabolites. These panels do not typically include assays for psilocybin or its metabolite, psilocin. For example, a standard 5-panel or 10-panel drug test will not screen for the presence of these compounds.
This low probability of detection stems from several factors, including the rapid metabolization of psilocybin in the body and the relatively short window of time during which it remains detectable. Furthermore, the cost and complexity of testing for psilocybin specifically are often prohibitive, making it an uncommon target for routine drug screenings. Historically, testing for psychedelic substances has been reserved for specific circumstances, such as forensic investigations or research studies.